MIM Software Inc. Receives FDA 510(k) Clearance for Additional AI Contours and Local Deployment

MIM Software Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for additional automatically segmented contours and local deployment for Contour ProtégéAI, its robust AI auto-contouring solution

November 3, 2021 — MIM Software Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for additional automatically segmented contours and local deployment for Contour ProtégéAI, its robust AI auto-contouring solution.

MIM Software has received FDA 510(k) clearance for additional head and neck, thorax, prostate, and abdomen contours. Quality improvements to existing contours have also been implemented.

Furthermore, Contour ProtégéAI now supports both cloud-hosted and local deployment in the United States.

"Contouring continues to be one of the most time-consuming tasks for radiation therapy clinics," said Andrew Nelson, Chief Executive Officer of MIM Software Inc. "MIM Software is dedicated to the continued development of Contour ProtégéAI to reduce the time required to contour and help clinics achieve quicker simulation to treatment times. This FDA 510(k) clearance significantly expands our offering and supports our ultimate goal of enhancing patient care."

Further enhancements will be pursued by MIM Software through additional FDA 510(k) clearances with the goal of pushing the capabilities of AI auto-contouring forward.

For more information: www.mimsoftware.com